The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 25, 2014

Filed:

Sep. 04, 2009
Applicants:

Mary L. Houchin, Rockville, MD (US);

Robin H. Lee, San Diego, CA (US);

Hong Qi, San Diego, CA (US);

Greg Oehrtman, San Diego, CA (US);

Robert N. Jennings, San Diego, CA (US);

Scott H. Coleman, San Diego, CA (US);

Inventors:

Mary L. Houchin, Rockville, MD (US);

Robin H. Lee, San Diego, CA (US);

Hong Qi, San Diego, CA (US);

Greg Oehrtman, San Diego, CA (US);

Robert N. Jennings, San Diego, CA (US);

Scott H. Coleman, San Diego, CA (US);

Assignees:

Amylin Pharmaceuticals, LLC, San Diego, CA (US);

AstraZeneca Pharmaceuticals LP, Wilmington, DE (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01); A61K 38/22 (2006.01); A61K 47/14 (2006.01); A61K 31/00 (2006.01); A61K 45/06 (2006.01); A61K 9/10 (2006.01); A61K 47/44 (2006.01); A61K 31/65 (2006.01); A61K 31/60 (2006.01);
U.S. Cl.
CPC ...
A61K 31/00 (2013.01); A61K 9/5153 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 38/2278 (2013.01); A61K 47/14 (2013.01); A61K 45/06 (2013.01); A61K 9/0019 (2013.01); A61K 9/10 (2013.01); A61K 47/44 (2013.01); A61K 31/65 (2013.01); A61K 31/60 (2013.01);
Abstract

The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.


Find Patent Forward Citations

Loading…